Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) was the recipient of a significant decline in short interest in the month of July. As of July 15th, there was short interest totalling 2,440,000 shares, a decline of 6.2% from the June 30th total of 2,600,000 shares. Based on an average daily trading volume, of 709,300 […]
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “overweight” rating reaffirmed by investment analysts at Morgan Stanley in a research note issued on Friday, Benzinga reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock. Morgan Stanley’s price objective would indicate a potential upside of 35.20% from the stock’s current […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) – Cantor Fitzgerald decreased their FY2023 EPS estimates for shares of Intra-Cellular Therapies in a report issued on Tuesday, July 25th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will earn ($2.27) per share for the year, down from their previous forecast of ($2.25). The […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) – Stock analysts at SVB Leerink cut their FY2025 earnings per share estimates for Intra-Cellular Therapies in a research report issued to clients and investors on Sunday, July 23rd. SVB Leerink analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of $1.45 for […]
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) saw a significant decrease in short interest in the month of June. As of June 30th, there was short interest totalling 2,600,000 shares, a decrease of 22.2% from the June 15th total of 3,340,000 shares. Based on an average daily volume of 734,500 shares, the short-interest ratio […]